Managed care
Southern California Permanente Medical Group
Southern California Permanente Medical Group was paid $52.84M by Medicaid between Jan 2018 and Dec 2024, across 399 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 31% of everything it billed.
33Billing provider infoSOUTHERN CALIFORNIA PERMANENTE MEDICAL GROUP
BELLFLOWER, CA 90706
BELLFLOWER, CA 90706
33aNPI1043242555assigned 07/07/2006
33bProvider typeHealth Maintenance Organization
28Total paid$52.84M
24GClaims2,033,419
24DCodes billed399
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Health Maintenance Organization providers in California
Rank by total paid#1 of 151
Median peer was paid$59K
This provider vs. median894×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official DAVIDOFF, RAMIN controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 211,671 | $268K | |
| 2019 | 260,812 | $782K | |
| 2020 | 191,934 | $3.62M | |
| 2021 | 255,968 | $7.33M | |
| 2022 | 280,171 | $8.53M | |
| 2023 | 359,301 | $12.91M | |
| 2024incomplete | 473,562 | $19.41M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 31% | 216,688 | 211,311 | $16.34M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 13% | 69,343 | 68,734 | $6.92M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 7.5% | 180,973 | 176,107 | $3.98M |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 3.7% | 33,204 | 27,745 | $1.93M |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | 2.4% | 25,500 | 25,306 | $1.26M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.3% | 9,473 | 9,409 | $1.20M |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 2.0% | 161,315 | 160,872 | $1.04M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.9% | 9,802 | 9,702 | $1.03M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.6% | 5,212 | 3,774 | $855K |
| 90662 | 1.5% | 7,051 | 7,030 | $791K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.5% | 47,987 | 46,333 | $786K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.2% | 22,907 | 17,206 | $622K |
387 more codes
| 70450 | Computed tomography, head or brain; without contrast material | 1.2% | 10,990 | $617K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 1.1% | 22,022 | $593K |
| 99283 | Emergency room visit (moderate) | <1% | 12,059 | $495K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 2,104 | $485K |
| 99441 | <1% | 13,015 | $469K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 11,708 | $408K |
| 92015 | Determination of refractive state | <1% | 44,506 | $401K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 4,375 | $390K |
| 92002 | <1% | 9,728 | $305K | |
| 11721 | <1% | 3,303 | $303K | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 15,126 | $295K |
| 71045 | Radiologic examination, chest; single view | <1% | 48,612 | $285K |
| 0001A | <1% | 6,967 | $271K | |
| 0002A | <1% | 6,747 | $266K | |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 3,504 | $242K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 21,195 | $230K |
| 92557 | <1% | 5,401 | $230K | |
| 99442 | <1% | 3,560 | $227K | |
| 90686 | <1% | 53,824 | $215K | |
| 90837 | Psychotherapy session, about an hour | <1% | 5,244 | $206K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 7,791 | $198K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 3,401 | $196K |
| 0064A | <1% | 4,463 | $184K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 9,521 | $181K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 13,132 | $160K |
| 95806 | <1% | 1,297 | $157K | |
| 0012A | <1% | 4,117 | $157K | |
| 73562 | <1% | 8,714 | $157K | |
| 0011A | <1% | 4,217 | $155K | |
| 77080 | <1% | 5,440 | $152K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 2,867 | $147K |
| 92551 | <1% | 52,266 | $143K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 17,764 | $140K |
| 90674 | <1% | 11,685 | $137K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 5,691 | $135K |
| 20610 | <1% | 1,132 | $130K | |
| 67028 | Intravitreal injection of a pharmacologic agent | <1% | 545 | $129K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 7,354 | $120K |
| 73030 | <1% | 7,301 | $119K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 13,780 | $118K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 629 | $118K |
| 72100 | <1% | 6,285 | $116K | |
| 92567 | <1% | 7,485 | $115K | |
| 90750 | <1% | 1,303 | $115K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 6,271 | $114K |
| 85610 | <1% | 23,619 | $105K | |
| 97161 | <1% | 1,357 | $104K | |
| 0124A | <1% | 3,006 | $103K | |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 1,817 | $102K |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 2,787 | $101K |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 1,366 | $98K |
| 73630 | <1% | 9,297 | $97K | |
| 84460 | <1% | 13,054 | $96K | |
| J0897 | Injection, denosumab, 1 mg | <1% | 42 | $96K |
| 82565 | <1% | 13,672 | $95K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 759 | $95K |
| 84075 | <1% | 11,795 | $91K | |
| 82247 | <1% | 14,726 | $89K | |
| 74183 | <1% | 157 | $86K | |
| 0134A | <1% | 2,290 | $84K | |
| 73502 | <1% | 2,401 | $83K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 5,668 | $82K |
| 82962 | <1% | 7,851 | $81K | |
| 0071A | <1% | 1,978 | $80K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 195 | $80K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 199 | $78K |
| 91320 | <1% | 364 | $76K | |
| 0004A | <1% | 1,883 | $76K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 391 | $75K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,139 | $74K |
| 0054A | <1% | 1,758 | $73K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 7,015 | $72K |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | <1% | 293 | $65K |
| 80051 | <1% | 8,784 | $65K | |
| 81003 | <1% | 38,613 | $64K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 944 | $64K |
| 0072A | <1% | 1,560 | $63K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 24,056 | $62K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 3,522 | $61K |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 729 | $60K |
| 73610 | <1% | 6,397 | $59K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 84 | $59K |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 27,423 | $57K |
| 99219 | <1% | 407 | $56K | |
| 82570 | <1% | 9,755 | $54K | |
| 76770 | <1% | 1,044 | $53K | |
| 73560 | <1% | 3,361 | $52K | |
| 92523 | <1% | 947 | $52K | |
| 82310 | <1% | 6,131 | $52K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 4,223 | $51K |
| 73130 | <1% | 3,651 | $49K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 2,653 | $46K |
| 84450 | <1% | 5,642 | $44K | |
| 76830 | Ultrasound, transvaginal | <1% | 3,528 | $42K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,687 | $42K |
| 76536 | <1% | 600 | $39K | |
| 99443 | <1% | 440 | $38K | |
| 93280 | <1% | 170 | $36K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 290 | $35K |
| 90651 | <1% | 1,716 | $34K | |
| 90656 | <1% | 6,809 | $33K | |
| 72040 | <1% | 1,571 | $32K | |
| 86360 | <1% | 880 | $32K | |
| 83735 | <1% | 3,837 | $31K | |
| 99223 | Prolong inpt eval add15 m | <1% | 324 | $31K |
| 84156 | <1% | 9,883 | $31K | |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 59 | $30K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 36 | $29K |
| G2012 | Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion | <1% | 76,218 | $29K |
| 81002 | <1% | 10,078 | $28K | |
| 73564 | <1% | 1,327 | $28K | |
| 73110 | <1% | 2,364 | $28K | |
| 17110 | <1% | 202 | $26K | |
| 86359 | <1% | 880 | $26K | |
| 90480 | <1% | 420 | $25K | |
| 74018 | <1% | 4,012 | $25K | |
| 73100 | <1% | 1,985 | $25K | |
| 83615 | <1% | 4,269 | $25K | |
| 91200 | <1% | 759 | $24K | |
| 72050 | <1% | 687 | $24K | |
| 93296 | <1% | 408 | $24K | |
| J7999 | Compounded drug, not otherwise classified | <1% | 377 | $23K |
| 73140 | <1% | 2,969 | $23K | |
| 83690 | <1% | 5,127 | $22K | |
| 52000 | <1% | 51 | $22K | |
| 97165 | <1% | 903 | $21K | |
| 0031A | <1% | 543 | $21K | |
| 90734 | <1% | 460 | $21K | |
| 71101 | <1% | 593 | $19K | |
| 72141 | <1% | 119 | $19K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 22,072 | $18K |
| 98968 | <1% | 900 | $17K | |
| 90677 | <1% | 672 | $17K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,636 | $17K |
| 70496 | <1% | 119 | $17K | |
| 81329 | <1% | 869 | $17K | |
| 90966 | <1% | 28 | $16K | |
| 99173 | <1% | 31,169 | $16K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 1,010 | $16K |
| 82947 | <1% | 6,862 | $16K | |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 992 | $15K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,519 | $13K |
| 73080 | <1% | 1,216 | $13K | |
| 93971 | <1% | 127 | $13K | |
| 90694 | <1% | 127 | $13K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 391 | $13K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 425 | $13K |
| 95117 | <1% | 1,876 | $13K | |
| 76641 | <1% | 428 | $13K | |
| 72070 | <1% | 558 | $13K | |
| 99177 | <1% | 10,391 | $12K | |
| 70498 | <1% | 81 | $12K | |
| 85027 | <1% | 7,804 | $12K | |
| 90670 | <1% | 1,392 | $12K | |
| 93295 | <1% | 147 | $12K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 278 | $12K |
| 73221 | <1% | 77 | $12K | |
| 83921 | <1% | 434 | $12K | |
| 99309 | Subsequent nursing facility care, per day, low to moderate complexity | <1% | 2,763 | $12K |
| 73590 | <1% | 1,121 | $12K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,530 | $11K |
| 0154A | <1% | 292 | $11K | |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | <1% | 39 | $11K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 365 | $11K |
| 82040 | <1% | 1,841 | $10K | |
| 97597 | <1% | 114 | $10K | |
| 81015 | <1% | 3,078 | $10K | |
| 97162 | <1% | 139 | $10K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 410 | $10K |
| 76801 | <1% | 378 | $10K | |
| 73660 | <1% | 892 | $10K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 274 | $9K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 81 | $9K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 13 | $9K |
| 84520 | <1% | 2,835 | $9K | |
| 62322 | <1% | 38 | $9K | |
| 72110 | <1% | 166 | $9K | |
| 71250 | <1% | 67 | $8K | |
| 85730 | <1% | 2,336 | $8K | |
| 73552 | <1% | 230 | $8K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 215 | $8K |
| 73522 | <1% | 164 | $8K | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 2,202 | $8K |
| 73060 | <1% | 217 | $7K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 1,169 | $7K |
| 84132 | <1% | 1,018 | $7K | |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | <1% | 480 | $7K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 160 | $7K |
| 86141 | <1% | 977 | $7K | |
| 82248 | <1% | 1,389 | $7K | |
| 90672 | <1% | 1,889 | $7K | |
| 0074A | <1% | 193 | $7K | |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 106 | $7K |
| 0052A | <1% | 166 | $7K | |
| 93294 | <1% | 93 | $7K | |
| 94060 | <1% | 75 | $7K | |
| 90678 | <1% | 38 | $7K | |
| 87210 | <1% | 6,226 | $6K | |
| 99201 | <1% | 1,442 | $6K | |
| 92587 | <1% | 1,082 | $6K | |
| 81206 | <1% | 43 | $6K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 416 | $6K |
| 0051A | <1% | 139 | $6K | |
| 11056 | <1% | 40 | $5K | |
| 72170 | <1% | 226 | $5K | |
| 43235 | <1% | 12 | $5K | |
| 82105 | <1% | 1,057 | $5K | |
| 88304 | <1% | 937 | $5K | |
| 73090 | <1% | 750 | $4K | |
| 82950 | <1% | 4,168 | $4K | |
| 84155 | <1% | 900 | $4K | |
| 0013A | <1% | 101 | $4K | |
| 0082A | <1% | 105 | $4K | |
| 11055 | <1% | 54 | $4K | |
| 84100 | <1% | 608 | $4K | |
| 76813 | <1% | 347 | $4K | |
| 0081A | <1% | 97 | $4K | |
| 99234 | <1% | 53 | $4K | |
| 90648 | <1% | 2,264 | $3K | |
| 99221 | <1% | 100 | $3K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 141 | $3K |
| 73070 | <1% | 358 | $3K | |
| 93304 | <1% | 61 | $3K | |
| 0112A | <1% | 77 | $3K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 302 | $3K |
| 51798 | <1% | 160 | $3K | |
| 73120 | <1% | 387 | $3K | |
| 73523 | <1% | 38 | $3K | |
| 64615 | <1% | 13 | $3K | |
| 74178 | <1% | 14 | $3K | |
| 90723 | <1% | 587 | $3K | |
| 90660 | <1% | 517 | $3K | |
| 81025 | <1% | 1,323 | $3K | |
| 88342 | <1% | 66 | $3K | |
| 92134 | <1% | 134 | $2K | |
| 77072 | <1% | 835 | $2K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 385 | $2K |
| 72081 | <1% | 331 | $2K | |
| S9480 | Intensive outpatient psychiatric services, per diem | <1% | 30 | $2K |
| 90715 | <1% | 141 | $2K | |
| 72080 | <1% | 39 | $2K | |
| 73565 | <1% | 53 | $2K | |
| 82951 | <1% | 673 | $2K | |
| 94729 | <1% | 14 | $2K | |
| G0127 | Trimming of dystrophic nails, any number | <1% | 30 | $2K |
| 94726 | <1% | 14 | $2K | |
| 93970 | <1% | 27 | $2K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 181 | $2K |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 115 | $2K |
| 0003A | <1% | 43 | $2K | |
| 92579 | <1% | 301 | $2K | |
| 11750 | <1% | 24 | $2K | |
| 81229 | <1% | 19 | $2K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,137 | $2K |
| 73000 | <1% | 143 | $2K | |
| 76881 | <1% | 77 | $1K | |
| 73600 | <1% | 155 | $1K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 36 | $1K |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 126 | $1K |
| 99460 | <1% | 370 | $1K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,838 | $1K |
| 0111A | <1% | 31 | $1K | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 528 | $1K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 818 | $1K |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 298 | $1K |
| 77073 | <1% | 25 | $1K | |
| 99383 | <1% | 44 | $1K | |
| 99188 | <1% | 390 | $1K | |
| 95819 | <1% | 16 | $1K | |
| 99235 | <1% | 12 | $1K | |
| 20553 | <1% | 12 | $1K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 702 | $998.87 |
| 77065 | Tomosynthesis, mammo | <1% | 28 | $980.00 |
| 72220 | <1% | 29 | $916.00 | |
| 20600 | <1% | 12 | $916.00 | |
| 11720 | <1% | 12 | $909.00 | |
| 99417 | Prolong home eval add 15m | <1% | 131 | $901.76 |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 126 | $806.57 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 144 | $787.39 |
| 97116 | <1% | 14 | $742.00 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 609 | $706.07 |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 49 | $662.82 |
| 82952 | <1% | 672 | $623.46 | |
| 99051 | <1% | 65,564 | $577.50 | |
| G0101 | Cervical or vaginal cancer screening; pelvic and clinical breast examination | <1% | 56 | $540.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 27 | $536.24 |
| 74019 | <1% | 15 | $495.00 | |
| J3490 | Unclassified drugs | <1% | 14 | $489.60 |
| 0034A | <1% | 12 | $481.58 | |
| 99382 | <1% | 78 | $440.00 | |
| 73650 | <1% | 29 | $420.00 | |
| 90633 | <1% | 324 | $384.00 | |
| 94010 | <1% | 144 | $381.63 | |
| 83835 | <1% | 18 | $360.00 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 52 | $345.60 |
| 99386 | <1% | 13 | $340.00 | |
| 99308 | Subsequent nursing facility care, per day, straightforward | <1% | 192 | $329.78 |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 28 | $329.00 |
| 81001 | <1% | 53 | $323.97 | |
| 99205 | Prolong outpt/office vis | <1% | 12 | $300.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 91 | $286.45 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 691 | $272.80 |
| 90655 | <1% | 149 | $261.00 | |
| 99305 | <1% | 38 | $250.00 | |
| 87338 | <1% | 51 | $226.80 | |
| 95012 | <1% | 26 | $224.00 | |
| 86800 | <1% | 15 | $222.53 | |
| 0083A | <1% | 70 | $218.50 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 28 | $203.00 |
| 77061 | <1% | 12 | $200.00 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 128 | $160.56 |
| 99307 | <1% | 103 | $149.44 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 111 | $94.17 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 87 | $90.60 |
| 83498 | <1% | 29 | $88.20 | |
| 81243 | <1% | 17 | $80.00 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 12 | $66.24 |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 702 | $64.68 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 39 | $50.42 |
| 90785 | <1% | 177 | $46.00 | |
| 87807 | <1% | 41 | $35.00 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 29 | $29.95 |
| 90661 | <1% | 2,925 | $24.50 | |
| 82157 | <1% | 13 | $18.48 | |
| 90681 | <1% | 24 | $18.00 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 12 | $14.00 |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 92 | $13.92 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 148 | $8.53 |
| G9920 | Screening performed and negative | <1% | 15,923 | $0.25 |
| 90658 | 0% | 64 | $0.00 | |
| 87186 | 0% | 155 | $0.00 | |
| 83721 | 0% | 36 | $0.00 | |
| 85046 | 0% | 70 | $0.00 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 0% | 59 | $0.00 |
| 85014 | 0% | 476 | $0.00 | |
| 99401 | 0% | 221 | $0.00 | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 0% | 72 | $0.00 |
| 83970 | 0% | 19 | $0.00 | |
| 82274 | 0% | 191 | $0.00 | |
| 80061 | Lipid panel | 0% | 373 | $0.00 |
| 82465 | 0% | 12 | $0.00 | |
| 94664 | 0% | 13 | $0.00 | |
| 90700 | 0% | 29 | $0.00 | |
| 83540 | 0% | 70 | $0.00 | |
| 84439 | 0% | 94 | $0.00 | |
| 80164 | 0% | 13 | $0.00 | |
| 83718 | 0% | 12 | $0.00 | |
| 84295 | 0% | 18 | $0.00 | |
| 1036F | 0% | 50,236 | $0.00 | |
| 73620 | 0% | 116 | $0.00 | |
| 86140 | 0% | 161 | $0.00 | |
| 99024 | 0% | 1,385 | $0.00 | |
| 97010 | 0% | 35 | $0.00 | |
| 87081 | 0% | 41 | $0.00 | |
| 85652 | 0% | 1,012 | $0.00 | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | 0% | 61 | $0.00 |
| 82043 | 0% | 258 | $0.00 | |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | 0% | 13 | $0.00 |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | 0% | 41 | $0.00 |
| 87088 | 0% | 312 | $0.00 | |
| 84443 | Thyroid stimulating hormone (TSH) | 0% | 323 | $0.00 |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 0% | 28 | $0.00 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 0% | 125 | $0.00 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 0% | 59 | $0.00 |
| 92227 | 0% | 168 | $0.00 | |
| 82607 | 0% | 56 | $0.00 | |
| 90716 | 0% | 14 | $0.00 | |
| 87070 | 0% | 14 | $0.00 | |
| 82728 | 0% | 73 | $0.00 | |
| 99462 | 0% | 13 | $0.00 | |
| 86308 | 0% | 16 | $0.00 | |
| 82784 | 0% | 12 | $0.00 | |
| 87340 | 0% | 15 | $0.00 | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 0% | 59 | $0.00 |
| 3044F | 0% | 270 | $0.00 | |
| 84153 | 0% | 40 | $0.00 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 0% | 12 | $0.00 |
| 85018 | 0% | 188 | $0.00 | |
| 86803 | 0% | 14 | $0.00 | |
| 90847 | Family psychotherapy with the patient present, 50 minutes | 0% | 59 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 12 | $0.00 |
| 83550 | 0% | 64 | $0.00 | |
| 86780 | 0% | 32 | $0.00 | |
| 82746 | 0% | 12 | $0.00 | |
| 97166 | 0% | 15 | $0.00 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 0% | 12 | $0.00 |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDAVIDOFF, RAMIN (EXECUTIVE MEDICAL DIRECTOR)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.